Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 10, 2008

Inverness Inks Licensing Deal with BioCurex to Advance Oncology Diagnostics

  • Inverness Medical Innovations licensed BioCurex’ RECAF™ material and technology. RECAF (the receptor for alpha-fetoprotein) is a wide-spectrum marker present in malignant cancer cells and absent in most normal cells, the companies explain. It will thus play a role in the development of diagnostic tests for prostate, breast, colorectal, lung and other cancers.

    Under terms of the agreement, Inverness will obtain semiexclusive, worldwide rights to commercialize products using this technology. BioCurex will be paid upfront fees, product and development milestones, plus royalties on product sales.

    “BioCurex’s RECAF technology complements the recent acquisition of Matritech and the equity investment in Diamics and should enhance our product development efforts in these areas,” comments Ferran Prat, vp of oncology for Inverness. “As only the second diagnostic manufacturer with access to RECAF, this agreement represents an important competitive step for Inverness within the oncology diagnostics, and monitoring markets.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »